Fluticasone Propionate and Formoterol Fumarate
- Generic Name
- Fluticasone Propionate and Formoterol Fumarate
- Indication
用于治疗哮喘。
Flutiform® Compared With Seretide® in the Treatment of COPD
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 923
- Registration Number
- NCT02195375
Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.
Phase 2
Completed
- Conditions
- Mild Persistent Asthma
- Interventions
- Drug: Beclometasone Autohaler 50 ug (2 puffs bid)
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 48
- Registration Number
- NCT02063139
- Locations
- 🇩🇰
Asthma and Allergy Children's Clinic, Randers, Denmark
A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 1767
- Registration Number
- NCT01946620
Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 498
- Registration Number
- NCT01511367
- Locations
- 🇭🇺
Illés és Ádám Egészségügyi Szolgáltató Bt., Kiskunhalas, Hungary
🇨🇿Alergologie Skopkova s.r.o, Ostrava-Marianske Hory, Czechia
🇵🇱Alergo-Med Specjalistyczna Przychodnia Lekarska Sp.z.o.o., Tarnow, Poland
Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma
- First Posted Date
- 2010-04-07
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 261
- Registration Number
- NCT01099722
- Locations
- 🇭🇺
Csongrád Megyei Önkormányzat Mellkasi Betegségek Szakkórháza Tüdőgondozó Intézet, Szeged, Hungary
Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma
Phase 3
Completed
- Conditions
- Asthma, Bronchial
- Interventions
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 1667
- Registration Number
- NCT00734318
A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2008-12-01
- Lead Sponsor
- SkyePharma AG
- Target Recruit Count
- 160
- Registration Number
- NCT00657774
- Locations
- 🇺🇸
Investigational Site, Lake Oswego, Oregon, United States
🇺🇸Investigational site, San Antonio, Texas, United States
A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2010-08-27
- Lead Sponsor
- SkyePharma AG
- Target Recruit Count
- 438
- Registration Number
- NCT00649025
- Locations
- 🇺🇸
Investigational site, Richmond, Virginia, United States
🇺🇦Investigational Site, Zaporizhzhya, Ukraine
An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 227
- Registration Number
- NCT00563056
- Locations
- 🇳🇱
Research site, Nieuwegein, Netherlands
🇬🇧Research Site, Chesterfield, United Kingdom
Study of FLUTIFORM® VS Seretide® in Paediatric Subjects With Asthma
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 211
- Registration Number
- NCT00475813
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath